EP Patent

EP2037931A2 — Pharmaceutical combinations of pk inhibitors and other active agents

Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2009-03-25 · 17y expired

What this patent protects

The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R1, Q1, Q2, E, G, T, R4, J1…

USPTO Abstract

The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R1, Q1, Q2, E, G, T, R4, J1 and J2 are as defined in the claims; or (II) a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein R1, R2, R3, R4, E, A, T, J1 and J2 are as defined in the claims.

Drugs covered by this patent

Patent Metadata

Patent number
EP2037931A2
Jurisdiction
EP
Classification
—
Expires
2009-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Cancer Research Royal Cancer Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.